A critical caveat, however, is the failure to account for heterogeneity in tau-PET topography at a given disease stage (i.e., tau patterns in cognitively normal and prodromal stages or subtypes at dementia stage) [12–16]. The gene discussed is MAPT; the disease is dementia.